On behalf of niaid-DCR, facilitate the conduct of two, randomized trials as detailed below in i and II: i. A randomized blinded controlled trial of the safety and efficacy of investigational…

Active Awarded Last action

Contract number
75N91020F00009
Awardee
Awarding agency
Obligated
$89,563,956

Award facts

Contract value 66% obligated
  • $89,563,956.00 Current, with exercised options
  • $136,722,003.00 Potential, with all options
Completion date 79% complete
Current and potential, with all options
Funding agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 · Niaid DCR covid-19 trials - covid-19 - NCI federally funded research and development center (ffrdc) contract $5,946,332
Terminate for Convenience P00011 · EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI $0
Other Administrative Action P00010 $13,721,004
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Funding Only Action P00006 $0
Other Administrative Action P00005 $0
Exercise an Option P00004 $2,536,808
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Definitize Letter Contract P00001 $33,788,063
Original award $33,571,749
Show all 13

About this award

Written by GovTribe AI ·

This is a $136,722,003.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The contract is for Leidos to facilitate the conduct of two randomized clinical trials of investigational therapeutics for the treatment of COVID-19, with up to 2,000 subjects. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and serves as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute. The contract does not have a set-aside designation. It includes a subcontract with Social & Scientific Systems, Inc., a subsidiary of DLH Holdings Corp., to provide clinical research protocol support in Mexico for the NIAID COVID-19 trials.

Description

As the agency reported it.

On behalf of niaid-DCR, facilitate the conduct of two, randomized trials as detailed below in i and II: i. A randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of covid-19 (2,000 subjects

Quick answers

Who was awarded contract 75N91020F00009?

75N91020F00009 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on April 1, 2020.

How much is contract 75N91020F00009 worth?

The government has obligated $89,563,956 on 75N91020F00009. Its potential value, with all options, is $136,722,003.

Which agency awarded contract 75N91020F00009?

National Cancer Institute (National Institutes of Health) awarded 75N91020F00009, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).

Is contract 75N91020F00009 an order under another contract?

Yes. 75N91020F00009 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91020F00009 competed?

The extent of competition for 75N91020F00009 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login